RIAMET

This brand name is authorized in Australia, Austria, France, Japan, Netherlands, New Zealand, UK.

Active ingredients

The drug RIAMET contains a combination of these active pharmaceutical ingredients (APIs):

1	Artemether UNII C7D6T3H22J - ARTEMETHER
	Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
	Read more about Artemether
2	Lumefantrine UNII F38R0JR742 - LUMEFANTRINE
	Read more about Lumefantrine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RIAMET Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
P01BF01	Artemether and lumefantrine	P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01B Antimalarials → P01BF Artemisinin and derivatives, combinations
Discover more medicines within P01BF01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	5296R, 9498X
FR	Base de données publique des médicaments	65574434
GB	Medicines & Healthcare Products Regulatory Agency	26594
JP	医薬品医療機器総合機構	6419102F1024
NL	Z-Index G-Standaard, PRK	59331
NZ	Medicines and Medical Devices Safety Authority	14003, 9649